Grandbrothers/iStock Editorial via Getty Images Shares of Ocular Therapeutix ( NASDAQ: OCUL ) rose 6% Wednesday after the company said the FDA has determined that its Phase 3 SOL-R clinical trial is appropriate as a registrational study to support potential approval of Axpaxli as a treatment for wet age-related macular degeneration, or wet AMD. Ocular said it intends to use the SOL-R and SOL-1 studies as the basis for a New Drug Application for Axpaxli for wet AMD, according to a statement . Earlier Wednesday, Ocular reported a flat year-over-year Q2 net loss of $0.
26 per share on higher revenue of $16M. The company added that it had $459.7M in cash and equivalents as of the end of June, which should fund operations into 2028.
More on Ocular Therapeutix Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors Investor Day Slides Ocular Therapeutix, Inc. (OCUL) Investor Day Call Transcript Ocular Therapeutix Q2 2024 Earnings Preview Ocular Therapeutix jumps as TD Cowen upgrades to Buy and hikes PT.
